Se espera que el mercado de aspergillos sistémicos y candidiasis sistémica alcance los 8.247,5 millones de dólares en 2027, frente a los 6.056,3 millones de dólares de 2019. Se estima que el mercado crecerá a una tasa compuesta anual del 4,0 % de 2020 a 2027.
Candida Auris es un hongo que causa una grave amenaza para la salud mundial. Provoca enfermedades graves en pacientes hospitalizados en varios países, incluido Estados Unidos. Los pacientes pueden permanecer colonizados por C. auris durante mucho tiempo. Además, C. Auris puede persistir en superficies en entornos sanitarios. Esto puede resultar en la propagación de C. Auris entre pacientes en centros de atención médica. Según un informe de los CDC de 2021, se han encontrado casos estadounidenses de C. auris en pacientes que estuvieron recientemente en centros de atención médica en Egipto, India, Kenia, Kuwait, Pakistán, Sudáfrica, Corea del Sur, los Emiratos Árabes Unidos y Venezuela, que También tenemos casos documentados. Por tanto, puede tratarse de una infección adquirida en el hospital. La aparición de Candida Auris se considera uno de los problemas más graves asociados a la transmisión nosocomial y a las prácticas de control de infecciones en el entorno hospitalario. Además, los CDC declararon que se informaron 560 casos de infecciones por C. Auris en los EE. UU. hasta el 31 de enero de 2019. Además, a pesar de la ejecución de contramedidas para limitar las infecciones por hongos en las unidades de cuidados intensivos (UCI), se siguen observando y notificando casos. , con tendencia hacia un patrón endémico. Esto muestra la capacidad de C. Auris de persistir la infección en el entorno clínico, permitiendo su transmisión en el entorno de cuidados críticos. A diferencia de otras especies de Candida, C. Auris puede colonizar diferentes sitios anatómicos (p. ej., piel, axila, recto y heces) y contaminar el equipo y las superficies del hospital, creando un círculo vicioso de propagación, adquisición e infección, particularmente en las UCI. /p>
Además, según un informe del NCBI publicado en enero de 2020, el creciente número de viajes a países extranjeros y la exposición a la atención médica en países con transmisión extensa de C. Auris, así como el mayor flujo de inmigrantes, son factores que pueden contribuir a la rápida diseminación de esta especie. Además, se encontró una mayor frecuencia de C. auris en los hospitales públicos en comparación con los privados, lo que puede estar relacionado con el hacinamiento y las medidas de control de infecciones comprometidas. Además, 7 de cada 1.000 pacientes admitidos en UCI en toda la India están afectados por una infección por hongos, según un análisis preliminar de los datos recopilados por investigadores del Instituto de Postgrado de Educación e Investigación Médica de Chandigarh. Los datos se recopilaron de 27 UCI de hospitales de todo el país (11 hospitales gubernamentales y 16 hospitales privados). Por lo tanto, la creciente incidencia de infecciones fúngicas adquiridas en hospitales está creando la demanda de medicamentos que puedan prevenir la aspergilosis sistémica y la candidiasis sistémica. Es probable que esto, a su vez, impulse el crecimiento del mercado de aspergilosis sistémica y candidiasis sistémica.
Mercados regionales lucrativos para aspergilosis sistémica y candidiasis sistémica
Perspectivas del mercado
Aumento en la prevalencia de enfermedades fúngicas
La aspergilosis sistémica y la candidiasis sistémica son tipos de infecciones por hongos. La infección por aspergilosis es causada por mohos. Afecta principalmente al tracto respiratorio de un individuo. Es una infección pulmonar grave causada por Aspergillus, un hongo común que afecta a personas con sistemas inmunitarios debilitados o enfermedades pulmonares. Además, las infecciones fúngicas graves se producen debido a otros problemas de salud, como asma, cáncer, SIDA, trasplantes de órganos y terapias con corticosteroides. El diagnóstico temprano permite un tratamiento antimicótico rápido; sin embargo, esto a menudo se retrasa o no está disponible, lo que provoca enfermedades crónicas graves, la muerte o la ceguera. Por ejemplo, según el Journal of Fungi publicado en marzo de 2017, la pandemia del VIH/SIDA, la tuberculosis, la enfermedad pulmonar obstructiva crónica (EPOC), el asma y la creciente incidencia de cánceres son los principales impulsores de las infecciones por hongos en los países desarrollados y en desarrollo a nivel mundial. . Además, un informe publicado por los Institutos Nacionales de Salud de la Biblioteca Nacional de Medicina en octubre de 2017 afirmó que ~3.000.000 de casos de aspergilosis pulmonar crónica; ~223.100 casos de meningitis criptocócica que complica el VIH/SIDA; ~700.000 casos de candidiasis invasiva; ~500.000 casos de neumonía por Pneumocystis jirovecii; ~250.000 casos de aspergilosis invasiva; ~100 000 casos de histoplasmosis diseminada; más de 10.000.000 de casos de asma fúngica; y anualmente se producen alrededor de 1.000.000 de casos de queratitis fúngica en todo el mundo. Además, según un informe de los Centros para el Control y la Prevención de Enfermedades (CDC), se han observado ~1.595 casos de Candida Auris en diferentes estados de EE. UU.
Tipo Información
Según el tipo, el mercado de aspergilosis sistémica y candidiasis sistémica se segmenta en voriconazol, anfotericina b liposomal, azoles orales sistémicos, agentes antifúngicos tópicos y otros. En 2019, el segmento de azoles orales sistémicos tuvo la mayor participación del mercado. Se espera que el mismo segmento crezca al ritmo más rápido durante el período de pronóstico debido al creciente número de infecciones fúngicas invasivas.
Mercado global de aspergilosis sistémica y candidiasis sistémica, por producto - 2019 y 2027
Application Insights
Basado en la aplicación, la aspergilosis sistémica global y la El mercado de la candidiasis se segmenta en aspergilosis pulmonar crónica (CPA), aspergilosis broncopulmonar alérgica (ABPA), candidiasis gastrointestinal, tracto genitourinario, candidiasis y otras. En 2019, el segmento de aspergilosis broncopulmonar alérgica (ABPA) tuvo la mayor participación del mercado. Se espera que el mismo segmento crezca al ritmo más rápido durante el período de pronóstico.
Información estratégica
Los lanzamientos y aprobaciones de productos son las estrategias comúnmente adoptadas por las empresas para ampliar su presencia global y carteras de productos para satisfacer la creciente demanda de los consumidores. Los actores del mercado de aspergilosis sistémica y candidiasis sistémica están adoptando la estrategia de colaboración para ampliar la base de clientes en todo el mundo, lo que también les permite mantener su marca a nivel mundial.
Aspergilosis sistémica y sistémica Mercado de candidiasis: por tipo
- Azoles orales sistémicos
- Voriconazol
- Anfotericina B liposomal
- Agentes antifúngicos tópicos
- Otros
Mercado de aspergilosis sistémica y candidiasis sistémica: por aplicación
- Aspergilosis broncopulmonar alérgica (ABPA)
- Aspergilosis pulmonar crónica (CPA)
- Candidiasis gastrointestinal
- Candidiasis del tracto genitourinario
- Otros
Mercado de aspergilosis sistémica y candidiasis sistémica: por Geografía
- América del Norte
- Estados Unidos
- Canadá
- México
< li>Europa - Francia
- Alemania
- Italia
- Reino Unido
- España
- Resto de Europa
- Asia Pacífico (APAC)
- China
- India
- Corea del Sur
- Japón
- Australia
- Resto de Asia Pacífico
- Medio Oriente y Asia África (MEA)
- Sudáfrica
- Arabia Saudita
- EAU
- Resto de Medio Oriente y África África
- América del Sur y Central
- Brasil
- Argentina
- Resto de América del Sur
Perfiles de la empresa
- Novartis Ag
- Sanofi-Aventis
- Pfizer, Inc.
- Merck And Co., Inc.
- Enzon Pharmaceuticals Inc.
- Bayer Ag
- Astellas Pharma, Inc.
- Glaxosmithkline Plc
- Abbott
- Cipla
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The systemic aspergillosis and systemic candidiasis are the type of fungal infections. The aspergillosis infection is caused by molds and majorly affect the respiratory tract of an individual. The aspergillosis is not a severe condition but people with weakened immune system are prone to it. The candidiasis is caused by fungus called candida. The candidiasis is also known as thrush. The symptoms of candidiasis include patches in mouth and tongue. The treatment options for aspergillosis and candidiasis include drug therapy and surgery in some cases.
Driving factors for the market include rise in prevalence of fungal diseases and rising hospital acquired fungal infection. however, increasing resistance to antifungal drugs and side effects of antifungal drugs is likely to hamper the growth of the market during the forecast period.
Allergic bronchopulmonary aspergillosis (ABPA) have fastest growing segment among all segments.
The List of Companies - Systemic Aspergillosis and Systemic Candidiasis Market
- Novartis Ag
- Sanofi-Aventis
- Pfizer, Inc
- Merck And Co. Inc
- Enzon Pharmaceuticals, Inc
- Bayer Ag
- Astellas Pharma Inc
- Glaxosmithkline Plc
- Abbott
- Cipla
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Jan 2021
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2021
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Jan 2021
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Jan 2021
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2021
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2021
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Jan 2021
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Jan 2021
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)